Search

Your search keyword '"Morpholines pharmacokinetics"' showing total 647 results

Search Constraints

Start Over You searched for: Descriptor "Morpholines pharmacokinetics" Remove constraint Descriptor: "Morpholines pharmacokinetics"
647 results on '"Morpholines pharmacokinetics"'

Search Results

1. Simultaneous quantification of baloxavir marboxil and its active metabolite in human plasma using UHPLC-MS/MS: Application to a human pharmacokinetic study with different anticoagulants.

2. Development of an extended action fostemsavir lipid nanoparticle.

3. Hepatic Dysfunction Quantified by HepQuant DuO Outperforms Child-Pugh Classification in Predicting the Pharmacokinetics of Ampreloxetine.

4. Discovery of baloxavir sodium as a novel anti-CCHFV inhibitor: Biological evaluation of in vitro and in vivo.

5. Pharmacology and pharmacokinetics of tazemetostat.

6. Species-specific Bioactivation of Morpholines as a Causative of Drug Induced Liver Injury Observed in Monkeys.

7. Rivaroxaban population pharmacokinetic and pharmacodynamic modeling in Iranian patients.

8. A Pharmacokinetics-Time to Alleviation of Symptoms Model to Support Extrapolation of Baloxavir Marboxil Clinical Efficacy in Different Ethnic Groups with Influenza A or B.

9. Population Pharmacokinetics Analysis of Pemigatinib in Patients With Advanced Malignancies.

10. Dose-dependent bioavailability and tissue distribution of the ATR inhibitor AZD6738 (ceralasertib) in mice.

11. Evaluation of the clinical cardiac safety of pemigatinib, a fibroblast growth factor receptor inhibitor, in participants with advanced malignancies.

12. Inhibiting the Activity of ABCG2 by KU55933 in Colorectal Cancer.

13. Central Nervous System Distribution of an Opioid Agonist Combination with Synergistic Activity.

14. Evaluation of drug-drug interactions of pemigatinib in healthy participants.

15. Tirbanibulin: A New Topical Therapy for Actinic Keratoses With a Novel Mechanism of Action and Improved Ease of Use.

16. Surface expression of the immunotherapeutic target G D2 in osteosarcoma depends on cell confluency.

17. Small-molecule polymerase inhibitor protects non-human primates from measles and reduces shedding.

18. Quantitation of vistusertib by UHPLC-MS/MS in rat plasma and its application to a pharmacokinetic study.

19. Pharmacokinetics and Safety of Fosaprepitant Dimeglumine in Healthy Chinese Volunteers: Bioequivalence Study.

20. Multiple-dose clinical pharmacology of the selective orexin-1 receptor antagonist ACT-539313.

21. Fostamatinib: A Review in Chronic Immune Thrombocytopenia.

22. First-in-Human, Single- and Multiple-Ascending-Dose Studies in Healthy Subjects to Assess Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability of Iberdomide, a Novel Cereblon E3 Ligase Modulator.

23. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPH3127: A Phase I, Randomized, Double-Blind, Placebo-Controlled Trial.

24. Pharmacokinetics of Dexamethasone when Administered with Fosaprepitant for Chemotherapy-Induced Nausea and Vomiting and Differences in Dose-Dependent Antiemetic Effects.

25. A randomized phase 1 single-dose polysomnography study of ASP8062, a GABA B receptor positive allosteric modulator.

26. Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma.

27. Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial.

28. Pharmacokinetics, safety and metabolite profiling of minesapride, a novel 5-HT 4 receptor partial agonist, in healthy elderly and young subjects.

29. Pharmacodynamic and pharmacokinetic behavior of landiolol during dobutamine challenge in healthy adults.

30. Thorough QT/QTc Study Shows That a Novel 5-HT 4 Receptor Partial Agonist Minesapride Has No Effect on QT Prolongation.

31. The antiviral effects of baloxavir marboxil against influenza A virus infection in ferrets.

32. Visual stimuli induce serotonin release in occipital cortex: A simultaneous positron emission tomography/magnetic resonance imaging study.

33. Non-rigid Diarylmethyl Analogs of Baloxavir as Cap-Dependent Endonuclease Inhibitors of Influenza Viruses.

34. Pharmacokinetic analysis of mosapride following intravenous and oral administration in beagle dogs.

35. Baloxavir Marboxil 2% Granules in Japanese Children With Influenza: An Open-label Phase 3 Study.

36. Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2).

37. Pharmacokinetic functions of human induced pluripotent stem cell-derived small intestinal epithelial cells.

38. Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models.

39. Evaluation of the Reinforcing Strength of Phendimetrazine Using a Progressive-Ratio Schedule of Reinforcement in Rhesus Monkeys.

40. A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features.

41. Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses.

42. LC-MS/MS determination of buparlisib, a phosphoinositide 3 kinase inhibitor in rat plasma: Application to a pharmacokinetic study.

43. INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models.

44. Evaluating the Therapeutic Efficacy and Safety of Landiolol Hydrochloride for Management of Arrhythmia in Critical Settings: Review of the Literature.

45. Single- and Multiple-Dose Safety, Tolerability, and Pharmacokinetic Profiles of ASP8062: Results From 2 Phase 1 Studies.

46. Development of a validated LC-MS/MS method for quantification of phosphoinositide 3 kinase inhibitor GSK2636771: Application to a pharmacokinetic study in rat plasma.

47. Reversion of cardiac dysfunction by a novel orally available calcium/calmodulin-dependent protein kinase II inhibitor, RA306, in a genetic model of dilated cardiomyopathy.

48. The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor.

49. Open-Label Two-Dose Pilot Study of Landiolol for the Treatment of Atrial Fibrillation/Atrial Flutter in Caucasian Patients.

50. A Newly Established Murine Cell Line as a Model for Hepatocellular Cancer in Non-Alcoholic Steatohepatitis.

Catalog

Books, media, physical & digital resources